Competition watch dog raps pharma sector for non-competitive market moves
While the Competition Commission of India (CCI) note appreciates 'legitimate public policy objectives', it tries to determine the…
Author
The pharma play in Ayushman Bharat
With saturation in export markets and rising regulatory constraints, will we see a refocus on the domestic market, prodded by…
India’s FDC saga and other stories
Framing regulations is one thing, interpreting and implementing them quite another saga, allowing repeat offenders like Biomed to…
Putting the bite into our laws
The recent faulty hip implant episode proves that our laws have not evolved as fast as medical technology
Revitalising pharmacy education
While there are good intentions, it is the implementation which threatens the viability of initiatives like the Pharm D course…
Playing for global stakes
Most bigger pharma companies have moved to the next level of exports: the trade of intellectual property, in the form of clinical…
For emerging technologies in pharma, choosing the right solution is always a challenge
As pharma companies in India strive to tap opportunities in large emerging markets, lean manufacturing techniques will play a…
Fix DAVA portal, says industry to DGFT
Faced with delays at ports and possible product recalls, industry hopes the DGFT will fix the issues with the DAVA portal as well…
Will indigenisation, innovation and information lead to true independence?
In my Editors Note in last year's Independence Day special issue, I had asked: as we mark our 71st Independence Day this August…
Acing the value chain
It is ironical that a Chinese movie seems to have done what India's policy makers have been trying to do for many years: get China…